Treatment of Scleroderma-Associated ILD Flare

Introduction to Scleroderma-Associated ILD Management

The American College of Rheumatology strongly recommends against long-term glucocorticoids (>3-6 months) in SSc-ILD due to moderate-certainty evidence of scleroderma renal crisis risk, particularly at prednisone doses >15 mg daily 1, 2, 4

Glucocorticoids have a limited role only as a bridge therapy while transitioning to more definitive immunosuppressive treatment during an acute flare 1, 3
For rapidly progressive SSc-ILD with acute respiratory deterioration, pulse IV methylprednisolone (1000 mg daily for 3 days) may be considered, followed by moderate-dose oral prednisone (up to 60 mg daily) with rapid taper over weeks 2

The American College of Rheumatology recommends switching to mycophenolate if not already on it, as the preferred second-line agent based on trials in SSc-ILD and concerns about cyclophosphamide toxicity 1, 3
Adding or switching to rituximab is recommended, which has indirect evidence from four trials showing FVC stabilization or improvement in SSc-ILD 1, 3
Cyclophosphamide remains an option with indirect evidence from five trials showing FVC stabilization, though it is typically second-line due to its side effect profile 1, 3
Adding nintedanib is recommended, particularly for progressive fibrosing disease on HRCT, though it only slows FVC decline and has frequent GI side effects 1, 3, 4

Tocilizumab (162 mg subcutaneously weekly) is conditionally recommended for SSc-ILD progression, though it was primarily studied in early SSc-ILD 1, 3, 5
Pirfenidone is NOT recommended for SSc-ILD progression (it is only conditionally recommended for RA-ILD) 1, 3

Assess severity: Determine if this is rapidly progressive ILD requiring urgent intervention versus slower progression 2
If rapidly progressive: Consider pulse IV methylprednisolone for 3 days, then oral prednisone with rapid taper as bridge therapy 2
Simultaneously escalate immunosuppression: Switch to mycophenolate (preferred), add rituximab, switch to cyclophosphamide, or add nintedanib 1, 3, 4

Never rely on long-term glucocorticoids (>3-6 months) as maintenance therapy in SSc-ILD—this carries a strong recommendation against due to scleroderma renal crisis risk 1, 2, 3
Do not combine nintedanib with mycophenolate upfront unless there is documented progression on mycophenolate alone 4, 5
Rule out alternative etiologies (infections, lymphoproliferative disorders) before initiating high-dose steroids 2
Monitor closely for scleroderma renal crisis when any glucocorticoids are used, especially at doses >15 mg daily prednisone 2, 4

Daily respiratory status assessment and oxygen requirements during acute phase 2
Monitor for steroid complications: hyperglycemia, hypertension, avascular necrosis 2
Serial pulmonary function tests every 3-6 months 2
Appropriate laboratory monitoring based on the specific immunosuppressive agent chosen 1